HUHiroki A. Ueyama

Hiroki A. Ueyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroki A. Ueyama has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Percutaneous Coronary Intervention in Dialysis Patients: Insights from a Nationwide Registry Analysis

    by Toshiki Kuno, Yuriko Hiruma, Hibiki Orui, Hiroki A. Ueyama, Tomohiro Fujisaki, Tadao Aikawa, Robert W. Yeh, Marie‐France Poulin, James M. McCabe, Roger Laham, et al.

    Background: Trans‐radial intervention (TRI) has become the standard of care for percutaneous coronary intervention (PCI). However, in patients on dialysis, trans‐femoral intervention (TFI) remains predominant to preserve upper‐limb vessels for arteriovenous fistula despite heightened hemorrhagic risk. This study aimed to compare TRI and TFI in dialysis patients undergoing PCI. Methods: We used the National Cardiovascular Data Registry CathPCI Registry to compare patients on dialysis who underwent PCIs with TRI versus TFI from January 2018 to June 2025. An instrumental variable analysis with the institutional proportion of TRI use was performed to assess the risk of access‐site bleeding and other peri‐procedural outcomes. Results: Among 137,702 dialysis patients who underwent PCI, 28.3% of patients underwent TRI (n=38,901), while 71.7% patients underwent TFI (n=98,801). TRI was associated with a lower risk of bleeding at the access site (adjusted risk difference [aRD]: ‐0.35%; 95% confidence interval [CI]: ‐0.56% to ‐0.15%). Overall bleeding (aRD: ‐1.38%; 95% CI: ‐1.89% to ‐0.87%), access‐site hematoma (aRD: ‐0.86%; 95% CI: ‐1.13% to ‐0.60%), myocardial infarction (aRD: ‐0.21%; 95% CI: ‐0.39% to ‐0.03%), and mortality (aRD: ‐1.07%; 95% CI: ‐1.64% to ‐0.51%) were also less frequently observed in TRI. Conversely, TRI was associated with a higher risk of stroke (aRD: 0.23%; 95% CI: 0.001% to 0.45%), driven primarily by ischemic stroke. Conclusions: TRI was associated with a lower risk of bleeding events, but the effect size was modest. The higher observed stroke risk highlights a potential ischemic trade‐off and warrants further study.

  • Trends and Outcomes of Antithrombotic Strategies for Valve-in-Valve TAVR

    by Hiroki A. Ueyama, Patrick T. Gleason, Sreekanth Vemulapalli, Pratik Manandhar, Andrzej S. Kosinski, Stamatios Lerakis, John D’ANgelo, Brent Keeling, Isida Byku, George S. Hanzel, et al.


  • Comparison of Outcomes of Leadless Versus Transvenous Pacemakers Following Tricuspid Valve Surgery

    by Tomonari M. Shimoda, Yoshihisa Miyamoto, Hiroki A. Ueyama, Shinobu Itagaki, Tsuyoshi Kaneko, Hiroshi Gotanda, Kosuke Inoue, Shinichi Fukuhara, Gorav Ailawadi, Hiroo Takayama, et al.

    Background: Transvenous pacemaker implantation after tricuspid valve surgery may cause adverse outcomes due to lead–valve interactions. Although leadless pacemakers may mitigate these risks, empirical data remain limited. Methods: We compared outcomes of leadless versus transvenous pacemakers following tricuspid surgery using a target trial emulation framework. We analyzed Medicare beneficiaries aged ≥65 years who underwent tricuspid valve surgery and received a pacemaker during the index admission between 2017 and 2021, using propensity score matching weight analysis to control for confounders. Primary outcomes were in‐hospital death and 2‐year heart failure hospitalization. Secondary outcomes included 2‐year death. Results: We included 185 and 1336 patients in the leadless and transvenous groups, respectively. Use of leadless pacemakers increased from 6.3% in 2017 to 17.5% in 2021. Leadless pacemaker recipients more often underwent tricuspid valve replacement (29.2% versus 8.5%) while concomitant mitral surgery was less common (69.2% versus 86.8%). After adjustment, we found no evidence that in‐hospital death (adjusted odds ratio, 1.82 [95% CI, 0.65–5.13] for leadless) and 2‐year heart failure hospitalizations (subdistribution hazard ratio [HR], 0.88 [95% CI, 0.60–1.30] for leadless) differed between the 2 groups. We also found no evidence that 2‐year death (adjusted HR, 1.04 [95% CI, 0.69–1.57] for leadless) differed between groups. Conclusions: No statistically significant differences were detected between leadless versus transvenous pacemaker implantations after tricuspid valve surgery. However, CIs were wide, and a clinically meaningful difference in either direction cannot be excluded. The study may therefore be underpowered, and the absence of echocardiographic data limits assessment of tricuspid regurgitation, warranting prospective studies.

  • Outcomes of Percutaneous and Surgical Interventions of Right‐Sided Heart Masses in Older Patients: A Nationwide Comparative Study

    by Tomonari M. Shimoda, Yuriko Hiruma, Tadao Aikawa, Yoshihisa Miyamoto, Hiroki A. Ueyama, Kosuke Inoue, Eric A. Secemsky, Roger Laham, Yusuke Tsugawa, Toshiki Kuno

    Background: Percutaneous aspiration thrombectomy is increasingly used as an alternative to surgery for right‐sided heart masses, but nationwide data are limited. Methods: We analyzed Medicare fee‐for‐service beneficiaries aged ≥65 years who underwent percutaneous or surgical removal of right‐sided heart masses from 2016 to 2021. We examined the temporal change in the number of percutaneous and surgical cases. The association between procedural types and patient characteristics was assessed using a multivariable logistic regression analysis. The primary outcomes were in‐hospital and 2‐year death. Given baseline differences between groups, we reported overall outcomes from the unadjusted cohort and comparative outcomes after adjustment using propensity score matching. Results: A total of 831 patients were included (447 percutaneous, 384 surgical), with the proportion of percutaneous cases increasing from 45.8% in 2016 to 65.0% in 2021. Patients with thrombosis (adjusted odds ratio, 3.42 [95% CI, 2.14–5.46]) and infective endocarditis (adjusted odds ratio, 10.08 [95% CI, 5.39–18.85]) were more often treated with percutaneous interventions. In‐hospital and 2‐year death in the percutaneous group were 11.0% and 43.0%, respectively. In the surgery group, those were 21.1% and 42.9%, respectively. Propensity score matching yielded 221 pairs. In the matched cohort, in‐hospital death remained lower with the percutaneous group (10.4% versus 19.5%; P =0.01), while 2‐year death was similar (hazard ratio, 1.00 [95% CI, 0.74–1.34]). Conclusions: This study from a national database demonstrated that percutaneous intervention for right‐sided heart masses has become the predominant strategy compared with surgery. Further trials are required to compare efficacy and safety between these interventions.

  • UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves

    by Elsa Hebbo, John T. D’ANgelo, Anton Camaj, Anas T. Noman, Hiroki A. Ueyama, Liana T. Alcaro, Roger J. Laham, Gennaro Giustino, Mostafa Naguib, Adnan M. Halboni, et al.


  • Open Access

    Comparison of Intravascular Imaging–, Physiology‐, or Angiography‐Guided Approaches for Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis

    by Tetsuya Saito, Tadao Aikawa, Yuko Kiyohara, Hiroki A. Ueyama, Hisato Takagi, Jose Wiley, Eric A. Secemsky, Robert W. Yeh, Roger Laham, Akiko Maehara, et al.

    Background: Despite current guidelines recommending physiology‐ and intravascular imaging–guided percutaneous coronary intervention (PCI) in specific lesion subsets, angiography‐guided PCI remains common in practice. The comparative effectiveness of these strategies remains uncertain. We aimed to compare clinical outcomes of PCI guided by intravascular imaging or physiological assessment versus conventional angiography. Methods: We conducted a systematic review and network meta‐analysis of randomized controlled trials, searching PubMed and EMBASE up to May 31, 2025. Eligible studies compared at least 2 of the following 6 guidance modalities in PCI: angiography, intravascular ultrasound (IVUS), optical coherence tomography/optical frequency domain imaging, fractional flow reserve, angiography‐derived fractional flow reserve, and instantaneous wave‐free ratio. The primary outcome was trial‐defined major adverse cardiovascular events (MACEs). Hazard ratios (HRs) with 95% CIs were pooled using a frequentist random‐effects network meta‐analysis. Subgroup analyses assessed clinical presentation and guidance objectives such as decision making and procedural optimization. Results: We identified 43 randomized controlled trials involving 39 291 patients. IVUS‐guided PCI (HR, 0.69 [95% CI, 0.60–0.79]), optical coherence tomography/optical frequency domain imaging‐guided PCI (HR, 0.75 [95% CI, 0.63–0.90]), and fractional flow reserve–guided PCI (HR, 0.81 [95% CI, 0.70–0.95]) were associated with a lower risk of MACEs compared with angiography‐guided PCI. Furthermore, IVUS‐guided PCI was associated with a lower risk of MACEs compared with instantaneous wave‐free ratio–guided PCI (HR, 0.74 [95% CI, 0.55–1.00]). IVUS‐guided PCI reduced the risk of MACE in both acute coronary syndrome and non‐acute coronary syndrome patients. Conclusions: IVUS‐ and optical coherence tomography/optical frequency domain imaging–guided PCI were superior to angiography‐guided PCI in reducing MACEs. Among the physiology‐based approaches, only fractional flow reserve showed a clear benefit.


  • Open Access

    Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income Countries

    by Makoto Hibino, Hiroki A. Ueyama, Raj Verma, Hwee Teoh, Bobby Yanagawa, Deepak L. Bhatt, Subodh Verma


  • Open Access

    Long-Term Outcomes Following Catheter-Based Therapies in Older Adults With Acute Pulmonary Embolism

    by Atsuyuki Watanabe, Toshiki Kuno, Yoshihisa Miyamoto, Hiroki A. Ueyama, Hiroshi Gotanda, Sripal Bangalore, Yusuke Tsugawa


  • Open Access

    Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism

    by Atsuyuki Watanabe, Toshiki Kuno, Yoshihisa Miyamoto, Hiroki A. Ueyama, Hiroshi Gotanda, Sripal Bangalore, Yusuke Tsugawa


  • Transapical Transcatheter Mitral Valve Replacement After Failed Transcatheter Edge-to-Edge Repair

    by Daryoush Samim, Paul Sorajja, Jonas Lanz, Lukas Stolz, Domenico Angellotti, Jörg Hausleiter, Hendrik Ruge, Elmar W. Kuhn, Stephan Baldus, Laurin Ochs, et al.